The US Food and Drug Administration (FDA) has designated the drug Jardiance from Eli Lilly and Boehringer Ingelheim the status 'breakthrough,' which fasttracks the application of the substance against a special type of heart failure, Eli Lilly informs in a statement. The FDA further explains the special status with the promising results from a phase III trial with Jardiance in the above indication.
According to Eli Lilly, the study confirms that Jardiance is the first treatment to significantly improve conditions for adults with weakened left ventricle muscles.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.